Iga has broad international and Polish experience in the healthcare sector, with a main focus on HTA at national and hospital level, drug pricing and reimbursement, health insurance, public health and evidence-based decision making processes in health care.

She contributed her efforts significantly to the role of HTA in evidence-based decision making processes on pharmaceutical reimbursement in Poland. She played a major role in HTA capacity building in Poland supporting the establishment of Polish national HTA Agency.

She also contributed her leadership and networking skills to the implementation of HTA in Central Eastern Europe and internationally advising in e.g. Croatia, Moldovia, Bulgaria, Turkey.

She served in variety of managerial roles in public and private sector supporting evidence-based decision making in health care in Poland and abroad. She was the Director of Pharmaceutical Policy and Pharmacy Department at Ministry of Health, the Director of HTA Department at Polish HTA Agency and the Director of Control Department at National Health Fund HQ (public payer in Poland). She negotiated pharmaceutical reimbursement prices and Risk Sharing Schemes on behalf of Minister of Health while being the Economic Committee Member. She supported the establishment of global HTA benchmarking program at Center for Innovation in Regulatory Science in London, UK.

She served as a co-chair of ISPOR HTA Roundtable Europe for 3 years’ term (from 2019 to the end of 2022).

Starting June 2022 she has been co-chairing HB-HTA Interest Group at Health Technology Assessment international for 3 years’ term.

For several years she has been also cooperating with Medical University of Gdańsk which is also her Alma Mater.

After several years she is back to Health Policy Institute being nominated the Chairwoman of the Board with her main role to contribute to evidence-based policy in health care and to build capacity in that area based on her international and national experience.